Enhancing CRISPR based Therapeutic Interventions Via a Targeted Platform Tool
Award amount
$150,000Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Advanced Targeting Systems
- Proposal award date
- 2017-02-01
- Contract end date
- 2017-11-30
- UEI
- Z8PDT5YVMP24
- Solicitation number
- PA15-269
- Topic code
- 100
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Targeting a Poor Prognosis Marker for Tumor Therapy
- Selective Activation in Specific Neuronal Populations
- Inhibition of Neurotransmission in Specific Neuronal Populations
- Monoclonal Antibodies to Target Neuronal Populations
- Drug Development of a Chronic Pain Therapeutic
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing
Research funding history
15 SBIR/STTR records share this UEI (1995–2017). Reported award amounts total $2,304,907. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services